To assess the effect of erythropoietin (EPO)in augmentation of peri implant tissues.

Not Applicable

• Conditions: Health Condition 1: K055- Other periodontal diseases

• Registration Number: CTRI/2023/08/056074
• Lead Sponsor: one

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 August 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.Systemically healthy patients.

2.Patients with at least one implant placed with functional restoration, with keratinized tissue <= 1 mm, who were unable to maintain oral hygiene around implants.

3.Patient with thin gingival phenotype.

4.Peri-implant probing depth < 3 mm.

5.No signs of pre-existing peri-implantitis

Exclusion Criteria

1.Patients with systemic diseases that would have influenced bone or soft tissue metabolism,

2.Smoking habit of more than one pack per day and unwillingness to stop the habit,

3.Radiotherapy and/or chemotherapy in the past 12 months

4.Unwillingness to commit to a long-term maintenance program after treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Gingival augmentation of peri <br/ ><br>implant soft tissuesTimepoint: Baseline 3 months & 6 months

Secondary Outcome Measures

Name	Time	Method
Peri-implant probing depth (PIPD),Clinical attachment level (CAL),Papillary recession height,Interproximal width (IPW),Keratinized tissue width (KTW),Gingival index (GI),Plaque index (PI),Modified sulcular bleeding index (mSBI),Patient Reported Outcome Measures (PROMS) <br/ ><br>Timepoint: Baseline,3 months and 6 months